Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beth Israel Deaconess Medical Center
University of Washington
The First Affiliated Hospital with Nanjing Medical University
University of Ulm
Dana-Farber Cancer Institute
International Extranodal Lymphoma Study Group (IELSG)
Sun Yat-sen University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital with Nanjing Medical University
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
The First Affiliated Hospital of Nanchang University
University of Miami
BeiGene
Academic and Community Cancer Research United
University of Nebraska
University of Nebraska
University of Nebraska
University of Nebraska
Henan Cancer Hospital
Chinese PLA General Hospital
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Seoul National University Hospital
Universität des Saarlandes
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
University of Washington
University of Arizona
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Masonic Cancer Center, University of Minnesota
Beth Israel Deaconess Medical Center
Arbeitsgemeinschaft medikamentoese Tumortherapie
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
University of Arizona
Alliance for Clinical Trials in Oncology
Mayo Clinic